Follistatin-344: Muscle, Myostatin, and Hair Growth Applications

What Follistatin-344 Is

Follistatin is an endogenous protein that binds and neutralizes several TGF-β family members, most notably myostatin (also known as GDF-8). Myostatin is a negative regulator of skeletal muscle growth — animals and humans with natural myostatin deficiency develop substantial muscle hypertrophy.

Follistatin-344 is a specific isoform of the follistatin protein (344 amino acids), synthesized pharmaceutically for research and clinical use. It sequesters myostatin, freeing muscle tissue from this endogenous brake on growth.

The Myostatin Science Behind Follistatin

Myostatin (GDF-8) was identified in 1997, when mice lacking the gene developed roughly double the normal skeletal muscle mass [1]. In 2004 a child with a loss-of-function myostatin mutation was reported with marked muscle hypertrophy, which confirmed that the pathway is active in humans [2]. Follistatin binds myostatin and blocks its signaling. Transgenic mice that overproduce follistatin in muscle showed muscle mass increases comparable to myostatin knockout mice [3].

Follistatin-344 is a 344-amino-acid isoform of follistatin. That makes it a protein, far larger than the short peptides usually discussed in peptide therapy.

Muscle Biology

The muscle-related effects follow directly from myostatin inhibition:

• Increased muscle protein synthesis when myostatin is neutralized
• Muscle hypertrophy in treated animals
• Improved muscle function in disease models (muscular dystrophies, sarcopenia)
• Potentially faster recovery from muscle injury

These effects have been robustly demonstrated in animal models and in genetic knockouts of myostatin. Human therapeutic translation has been active — multiple pharmaceutical development programs for myostatin inhibitors have progressed through clinical trials — though full commercial approval as muscle-wasting therapeutics has been elusive.

What Research Reports on Results in Humans

All published human data on follistatin-344 come from gene therapy. In these trials a viral vector carrying the follistatin-344 gene was injected directly into muscle in small, open-label studies of patients with Becker muscular dystrophy or inclusion body myositis [5][6]. No published trial has tested injected follistatin-344 protein or peptide products, the form discussed in wellness settings, for muscle, body composition or hair in humans. Other follistatin gene-therapy studies are registered on ClinicalTrials.gov (for example NCT06411366), but they also test gene transfer, not an injectable peptide. The hair-growth rationale rests on mouse follicle biology [8].

The Hair Growth Application

The hair growth interest in follistatin is a more recent development and deserves explanation. Follistatin’s role in hair biology was described in research showing that:

• Hair follicle stem cells express components of the TGF-β signaling pathway
• BMP (bone morphogenetic protein) signaling contributes to hair follicle cycling
• Follistatin modulates BMP signaling and can influence hair follicle dynamics

Some research has explored follistatin as a potential treatment for hair loss, particularly in the context of hair follicle regeneration. The data are early — this is not a settled clinical application — but interest has grown, particularly in aesthetic medicine and hair restoration practice.

Clinical Use Patterns

In physician-supervised peptide practice, follistatin-344 has been used for:

• Muscle preservation in calorie deficit — preventing sarcopenia during weight loss
• Recovery support in athletic or post-injury contexts
• Body composition optimization alongside other peptides
• Emerging hair restoration protocols — more experimental

The combination of follistatin with growth hormone axis peptides (CJC-1295, ipamorelin) is occasionally used in protocols targeting aggressive body composition goals.

Dosing and Cycle Considerations

Dosing for follistatin-344 in compounding practice is typically:

• Subcutaneous administration
• Low-microgram doses per injection
• Often daily for defined cycle lengths
• Cycle length typically 10–14 days — shorter than many peptides, based on the potent myostatin inhibition
• Cycled with rest periods between active phases

Dosing should be confirmed with the prescribing physician and compounding pharmacy.

Safety Considerations

Potential safety concerns with follistatin-344:

• Tendon and connective tissue effects — some concern about rapid muscle growth outpacing tendon adaptation
• Cardiovascular considerations — myostatin has cardiac expression; effects on cardiac muscle require monitoring
• Cancer concerns — any pro-growth signal warrants caution in patients with current or recent malignancy
• Long-term safety — not well characterized in humans

The generally reported safety profile in short-cycle use has been favorable, but chronic use deserves caution.

Regulatory Status

Follistatin-344 is not FDA-approved and is not a standard component of pharmaceutical preparations. It is not on the 503A Bulks List or FDA's 503A category list and has not been scheduled for PCAC review.

October 2026 update: follistatin-344 is not FDA-approved. It is not on the 503A Bulks List and was not among the substances the PCAC voted on in July 2026 or those scheduled for its next meeting. Check current status in the FDA Peptide Status Tracker, and see the follistatin-344 research library page for the compound profile.

Key Takeaways

• Follistatin-344 inhibits myostatin and other TGF-β family members.
• The mechanism supports muscle growth, preservation, and recovery.
• Hair growth applications are emerging but early.
• Short cycle lengths (10–14 days) are typical; chronic use is less common.
• Safety concerns around connective tissue, cardiac, and long-term effects warrant careful patient selection.
• Regulatory access depends on 503A compounding; verification of current status required.

Frequently Asked Questions

How does follistatin-344 help muscle growth?

By binding and neutralizing myostatin, it removes a negative regulator of muscle growth, allowing increased muscle protein synthesis and hypertrophy.

Can follistatin-344 help with hair loss?

Research on follistatin in hair biology is emerging. This is an experimental application rather than a settled clinical indication.

How long should a follistatin-344 cycle be?

Typical cycles are 10–14 days, shorter than many peptides, based on the potent myostatin inhibition.

What are the side effects of follistatin-344?

Reported side effects in short-cycle use are generally mild. Concerns about tendon adaptation, cardiac effects, and long-term safety warrant careful monitoring.

Has follistatin-344 been tested in humans?

Only as gene therapy. Small open-label trials delivered the follistatin-344 gene into the thigh muscles of patients with Becker muscular dystrophy and inclusion body myositis, and some participants walked farther afterward [5][6]. No human trial of injected follistatin-344 peptide has been published.

Is follistatin-344 FDA-approved?

No. It is not approved for any indication and is not on the 503A Bulks List. See the FDA Peptide Status Tracker for current status.

Is follistatin a peptide or a protein?

Follistatin-344 is a 344-amino-acid protein isoform, much larger than typical therapeutic peptides such as BPC-157. Its main known action is binding and neutralizing myostatin and related TGF-β family signals [3].

References

1. McPherron AC, et al. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 1997;387(6628):83-90. PubMed
2. Schuelke M, et al. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med. 2004;350(26):2682-8. PubMed
3. Lee SJ, et al. Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci U S A. 2001;98(16):9306-11. PubMed
4. Kota J, et al. Follistatin gene delivery enhances muscle growth and strength in nonhuman primates. Sci Transl Med. 2009;1(6):6ra15. PubMed
5. Mendell JR, et al. A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. Mol Ther. 2015;23(1):192-201. PubMed
6. Mendell JR, et al. Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes. Mol Ther. 2017;25(4):870-879. PubMed
7. Wagner KR, et al. A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol. 2008;63(5):561-71. PubMed
8. Nakamura M, et al. Control of pelage hair follicle development and cycling by complex interactions between follistatin and activin. FASEB J. 2003;17(3):497-9. PubMed